To study the potential interaction between carbamazepine (CBZ) and sel
ective serotonin reuptake inhibitors, fluoxetine (20 mg/day) and fluvo
xamine (100 mg/day) were administered for 3 weeks to eight and seven e
pileptic patients, respectively, on chronic CBZ treatment. No signific
ant changes in steady-state plasma concentrations of CBZ and its activ
e metabolite, carbamazepine-10,11-epoxide (CBZ-E) occurred, suggesting
that CBZ metabolism is probably not affected by fluoxetine or fluvoxa
mine administration.